Lipin Liu¹, Nan Bi², Zhe Ji², Junling Li², Jingbo Wang², Xiaozhen Wang², Zhouguang Hui², Jima Lv², Jun Liang²,  Zongmei Zhou², Yan Wang², Weibo Yin², Luhua Wang²

 ¹Department of RadiationOncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences& Peking union   Medical College, ²Chinese Academy ofMedical

Sciences & Peking union   Medical College, CancerHospital and Institute

Objective:For patients with locally advancednon-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy(CCT) following concurrent chemoradiotherapy (CRT) is partially defined. The aimof this study was to evaluate the efficacy and toxicity of CCT. Method: Thecharacteristics of LA-NSCLC patients treated with curative concurrent CRT from2001 to 2010 were retrospectively reviewed. Result: Among 203 patients,113 (55.7%) patients received CCT. The median number of delivered CCT was 3 and89.4% patients completed ≥2 cycles. The OS was significantly better forpatients in the CCT group compared with that in the non-CCT group (median OS,27 months vs. 16 months; 5-year OS, 30.4% vs. 22.5%; P=0.012).The medianPFS were 12 months in the CCT group and 9 months in the non-CCT group (P=0.291).The survival advantages of CCT were significant for males (HR: 0.63; 95% CI,0.44−0.90), patients with age (HR: 0.63; 95% CI, 0.42−0.95), non-squamous histology(HR: 0.44; 95% CI, 0.25−0.76), pretreatment KPS≥80 (HR: 0.67; 95% CI,0.48−0.93), stage IIIb (HR: 0.64; 95% CI, 0.43−0.95) and SD (HR: 0.31; 95% CI,0.14−0.65). The risk of grade≥3 hematological toxicities was higher in the CCTgroup than in the non-CCT group, though not significant (45.1% vs. 34.4%; P=0.123).Conclusion: CCT might further prolong survival compared with CRT alonefor LA-NSCLC without increasing treatment-related toxicities, especially formales, patients with age.

Key Words: Locally advancednon-small-cell lung cancer  Consol